Compare · ELTX vs NVO
ELTX vs NVO
Side-by-side comparison of Elicio Therapeutics Inc. (ELTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 854.8x ELTX ($215.1M).
- Over the past year, ELTX is up 131.6% and NVO is down 34.2% - ELTX leads by 165.9 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for ELTX).
- NVO has more recent analyst coverage (25 ratings vs 2 for ELTX).
- Company
- Elicio Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $11.72-0.76%
- $41.18+6.93%
- Market cap
- $215.1M
- $183.82B
- 1M return
- +7.28%
- +13.32%
- 1Y return
- +131.62%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 5
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELTX
- Elicio Therapeutics Reports Inducement Grants
- Ladenburg Thalmann initiated coverage on Elicio Therapeutics with a new price target
- Elicio Therapeutics Reports Inducement Grants
- SEC Form EFFECT filed by Elicio Therapeutics Inc.
- Elicio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by Elicio Therapeutics Inc.
- SEC Form S-8 filed by Elicio Therapeutics Inc.
- Amendment: SEC Form S-3/A filed by Elicio Therapeutics Inc.
- SEC Form 10-K filed by Elicio Therapeutics Inc.
- Elicio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S